Shots:

• NICE has recommended Cosentyx as a cost-effective option for the treatment of mod. to sev. PsO in patients aged 6-17 yrs. who have not responded to other forms of systemic treatment & for whom these options were contraindicated or not tolerated
• Additionally- patients will now have access to this treatment option on the NHS. The therapy is supported through the sustained efficacy and safety data across psoriasis- PsA- and axSpA with 500-000+ patients treated globally
• Secukinumab (SC- q4w) is the first IL-17A inhibitor to be recommended by NICE & is approved in 90+ countries including the UK- in EU- US- Japan & China

Ref: Novartis | Image: Novartis